1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gastro-retentive Drug Delivery Systems Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gastro-retentive Drug Delivery Systems Outsourcing Market, by Drug Type
8.1.1. Biologics
8.1.1.1. Market Revenue and Forecast
8.1.2. Small Molecules
8.1.2.1. Market Revenue and Forecast
8.1.3. Generics
8.1.3.1. Market Revenue and Forecast
9.1. Gastro-retentive Drug Delivery Systems Outsourcing Market, by Technology
9.1.1. Floating Drug Delivery Systems
9.1.1.1. Market Revenue and Forecast
9.1.2. Swelling and Expanding Systems
9.1.2.1. Market Revenue and Forecast
9.1.3. Mucoadhesive Systems
9.1.3.1. Market Revenue and Forecast
10.1. Gastro-retentive Drug Delivery Systems Outsourcing Market, by Application
10.1.1. Anti-Ulcer Drugs
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiovascular Drugs
10.1.2.1. Market Revenue and Forecast
10.1.3. Anti-Inflammatory Drugs
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. Gastro-retentive Drug Delivery Systems Outsourcing Market, by Route of Administration
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast
11.1.2. Transdermal
11.1.2.1. Market Revenue and Forecast
11.1.3. Nasal
11.1.3.1. Market Revenue and Forecast
11.1.4. Rectal
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Type
12.1.2. Market Revenue and Forecast, by Technology
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by Route of Administration
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Type
12.1.5.2. Market Revenue and Forecast, by Technology
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by Route of Administration
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Type
12.1.6.2. Market Revenue and Forecast, by Technology
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by Route of Administration
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Type
12.2.2. Market Revenue and Forecast, by Technology
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by Route of Administration
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Type
12.2.5.2. Market Revenue and Forecast, by Technology
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by Route of Administration
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Type
12.2.6.2. Market Revenue and Forecast, by Technology
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by Route of Administration
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Type
12.2.7.2. Market Revenue and Forecast, by Technology
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by Route of Administration
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Type
12.2.8.2. Market Revenue and Forecast, by Technology
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by Route of Administration
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Type
12.3.2. Market Revenue and Forecast, by Technology
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by Route of Administration
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Type
12.3.5.2. Market Revenue and Forecast, by Technology
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by Route of Administration
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Type
12.3.6.2. Market Revenue and Forecast, by Technology
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by Route of Administration
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Type
12.3.7.2. Market Revenue and Forecast, by Technology
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by Route of Administration
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Type
12.3.8.2. Market Revenue and Forecast, by Technology
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by Route of Administration
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Type
12.4.2. Market Revenue and Forecast, by Technology
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by Route of Administration
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Type
12.4.5.2. Market Revenue and Forecast, by Technology
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by Route of Administration
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Type
12.4.6.2. Market Revenue and Forecast, by Technology
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by Route of Administration
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Type
12.4.7.2. Market Revenue and Forecast, by Technology
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by Route of Administration
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Type
12.4.8.2. Market Revenue and Forecast, by Technology
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by Route of Administration
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Type
12.5.2. Market Revenue and Forecast, by Technology
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by Route of Administration
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Type
12.5.5.2. Market Revenue and Forecast, by Technology
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by Route of Administration
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Type
12.5.6.2. Market Revenue and Forecast, by Technology
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by Route of Administration
13.1. Aptar Pharma
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Lonza Group
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent Pharma Solutions
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Evonik Industries
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Coloron, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Patheon
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Skyepharma
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Baxter Bio Pharma Solutions
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Recipharm
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Vetter Pharma
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
